Can evaluation of targeted therapy in oncology be improved by means of 18F-FLT?

Journal of Nuclear Medicine

Volumn 51, Issue 10, 2010, Pages 1499-1500

  De Saint Hubert, Marijke ^a   Brepoels, Lieselot ^a   Mottaghy, Felix M ^b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CYCLIN D1; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; RIDAFOROLIMUS; TEMSIROLIMUS; THYMIDINE KINASE 1;

CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL EVALUATION; DNA SYNTHESIS; DRUG UPTAKE; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; FALSE POSITIVE RESULT; HUMAN; INFLAMMATORY CELL; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY;

DIDEOXYNUCLEOSIDES; DRUG DELIVERY SYSTEMS; HUMANS; IMAGE ENHANCEMENT; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79851472458     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.079020     Document Type: Review

References (17)

1. 18F] FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging. 2002;29:1174-1181.
2. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202-4210.
3. 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393-401.
4. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659-1672. (Pubitemid 40104613)
5. 18F-FLT. J Nucl Med. 2008;49:135-141.
6. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735. (Pubitemid 47604972)
7. 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med. 2009;50:1102-1109.
8. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167-181.
9. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95:1148-1154. (Pubitemid 44660065)
10. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev. 2007;33:78-84. (Pubitemid 46132007)
11. Lavarino C, Pilotti S, Oggionni M, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol. 2000;18:3936-3945.
12. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13:4261-4270. (Pubitemid 47105991)
13. 18F] fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009;27:2697-2704.
14. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med. 2010;51:1559-1564.
15. 18F]FLT: portrait of a proliferation marker. Eur J Nucl Med Mol Imaging. 2002;29:165-169.
16. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.
17. 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med. 2010;51:845-853.